Oryzon Genomics - Final PORTICO data reaffirms potential in BPD
Oryzon has presented the results of the final analysis from the Phase IIb PORTICO trial, which evaluated the efficacy and safety of vafidemstat in...
257 Views
Oryzon Genomics - First patient dosed in new AML combination study
Oryzon Genomics has announced the commencement of patient dosing in the investigator-initiated Phase Ib trial evaluating iadademstat as a...
415 Views
Oryzon Genomics - Multiple milestones anticipated in H224
Oryzon’s Q224 results summarised an active quarter for its clinical pipeline, with multiple milestones expected in H224. Central to the H224...
285 Views
Oryzon Genomics - Strengthening vafidemstat’s IP profile
Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the...
197 Views
Oryzon Genomics - Encouraging interim update on FRIDA
Oryzon Genomics has reported positive interim data from the Phase Ib FRIDA study, evaluating iadademstat in combination with gilteritinib in...
326 Views